September 01, 2015

Symetis announces intention to float on SIX Swiss Exchange

Symetis is a leading Swiss medical technology company active in the fast growing TAVI (transcatheter aortic valve implantation) market • Offering of primary shares to raise approximately CHF 80 million, excluding 15% over-allotment option

Symetis SA, a leading Swiss medical technology company, focused on transcatheter aortic valve implantation (TAVI), announced today its intention to float its shares and list on SIX Swiss Exchange in 2015. Proceeds from the initial public offering (IPO) will enable the company to accelerate and expand its commercial activities in the EU, strengthen its proprietary product pipeline and technology platform, as well as expand its activity in Asia and the United States.
Download PDF - Press Release  English Version
Download PDF - Press Release German Version
Download PDF - Press Release French Version
 

read more »

August 21, 2015

Evolva launches nootkatone for F&F

US EPA letter facilitates potential approval as tick and insect repellent

Evolva (SIX: EVE) announces the launch of nootkatone, a highly prized citrus flavour and fragrance (F&F) ingredient. By brewing nootkatone from sugar, rather than extracting it from the skin of grapefruits, Evolva’s process allows nootkatone to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolva has now begun selling nootkatone as a F&F ingredient to food, beverage, personal care, and home care product producers around the world.
PDF Download - English Version
PDF Download - German Version

read more »

July 21, 2015

Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease

Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease (PD) experiencing levodopa related end-of-dose "wearing-off".
PDF Download

read more »

June 11, 2015

Biotie Announces Completion of Pricing of U.S. Public Offering of ADSs and Conversion of Convertible Notes

Biotie Therapies Corp. ("Biotie" or the "Company"), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has completed the pricing of its U.S. public offering of 3,761,418 ADSs at a price to the public of $14.888 per ADS for gross proceeds of $55,999,991.18 (€49,649,783.83 at the fixed ECB exchange rate of $1.1279 per euro as at June 10, 2015). The share to ADS ratio is 80 to one, and the ADSs will represent 300,913,440 newly issued shares in the Company with a subscription price of €0.165 (rounded figure) per new share (at the above mentioned fixed exchange rate).
PDF Download

read more »

June 08, 2015

Biotie Increases Proposed U.S. Public Offering of ADSs

Biotie Therapies Corp. ("Biotie" or the "Company"), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has decided to increase its proposed U.S. public offering from $50 million to $56 million American Depositary Shares ("ADSs") representing its shares.
PDF Download

read more »

June 04, 2015

Biotie Commences Proposed U.S. Public Offering of ADSs

Biotie Therapies Oyj, a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has today commenced the marketing of a proposed U.S. public offering of $50 million American Depositary Shares ("ADSs") representing its shares, based on the authorization granted by the Annual General Meeting of shareholders on May 26, 2015.
PDF Download

read more »

May 21, 2015

Chinese Consortium Enters into Agreement to Acquire Ambrx

A consortium (the “Consortium”) consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare fund (“CEL Healthcare Fund”), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions. Other details of the transaction were not disclosed.
PDF Download

read more »

May 20, 2015

Evolva CEO exercises options, increases his shareholding in Evolva

Evolva (SIX: EVE) today announces that Neil Goldsmith, CEO of Evolva, has exercised options that he held to acquire 3.8 million new Evolva shares, simultaneously selling 2.2 million of them to cover the acquisition costs and taxes related to the option transaction, leaving him with an additional 1.6 million shares.
PDF Download - English Version
PDF Download - German Version

read more »

May 14, 2015

¨Biotie Has Filed Registration Statement for U.S. Public Offering

In accordance with its previously announced plans, Biotie Therapies Corp. ("Biotie") has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to its proposed U.S. public offering of American Depositary Shares, representing Biotie's ordinary shares ("ADSs"). The number of ADSs to be offered and the price range for the offering have not yet been determined. Biotie has made an initial submission to list its ADSs on the NASDAQ Global Market under the ticker symbol "BITI".
PDF Download

read more »

May 11, 2015

Cargill and Evolva Start Engineering Work on Production Facility for Next-Gen Stevia Sweeteners

Evolva informs Cargill of intent to exercise 45% option

Evolva and Cargill have agreed to begin the engineering phase for converting an existing Cargill manufacturing facility to produce next-generation stevia sweeteners (steviol glycosides). The ingredients are expected to be commercially available in 2016.
PDF Download - English Version
PDF Download - German Version

read more »

April 23, 2015

ARAVIS sells two German wind farms

Aravis Energy I LP, a Swiss renewable energy fund advised by Aravis, successfully completed the sale of two companies comprising two German wind farms to a Swiss power supplier. “We have once again been able to successfully exit investments, which further strengthens our track record of delivering returns to investors. This proves our agility and high-quality skills of implementing attractive investment projects in accordance with the investment strategy.’’, commented Oliver Thalmann, Managing Partner of Aravis. The German wind farms are located in Rhineland-Palatinate respectively Brandenburg. Both wind farms benefit from attractive long-term feed-in tariffs. These tariffs do not correlate with other commodity market prices such as those for oil and gas, thereby offering an efficient diversification effect to investors.
PDF Download

read more »

April 23, 2015

Biotie provides update on tozadenant Phase 3 program

Biotie has further refined its plans for the design and conduct of Phase 3 trials in Parkinson's disease (PD) patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations). The phase 3 program will consist of a double- blind trial with an open-label extension and, providing this demonstrates safety and efficacy, will be followed by a separate open-label trial to generate further clinical safety data.
PDF Download

read more »

April 23, 2015

Evolva completes transfer of EV-035 to Emergent BioSolutions, triggering a USD 4 million payment

Evolva (SIX: EVE) today announces the US government’s approval of the transfer (“novation”) of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015.
PDF Download - English Version
PDF Download - German Version

read more »

April 15, 2015

Bilan, 15.04.2015 - L'etoile montante des medtech suisses

SYMETIS DOIT MAINTENANT CHANGER D'ECHELLE. CELA PASSE PAR SON RACHAT OU PAR UNE INTRODUCTION EN BOURSE

Apres une vague d'acquisitions , le  secteur  abesoin  de nouvelles  locomotives helvetiques.   En pleine  croissance, l'entreprise vaudoise  Symetis est une bonne  candidate.
PDF Download

read more »

March 31, 2015

Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis

Biotie Therapies Corp ("Biotie") announces the start of patient enrolment into the Phase 2a clinical study evaluating BTT1023, Biotie's fully human monoclonal antibody targeting Vascular Adhesion Protein-1, in primary sclerosing cholangitis (PSC). PSC is a progressive immune mediated biliary disease characterised by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis, that frequently results in the need for liver transplantation. The study is being funded through the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership*.
PDF Download

read more »

March 26, 2015

Evolva and Valent BioSciences to co-develop agricultural bioactives

Evolva (SIX: EVE) and Valent BioSciences Corporation (VBC), a subsidiary of Tokyo-based Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time.
PDF Download - English Version
PDF Download - German Version

read more »

March 10, 2015

Mallinckrodt to acquire Ikaria in $2.3 bln deal. Early investor Aravis Exits along side with PE Madison Dearborn

Ikaria is being sold for $2.3 billion to global biopharmaceutical company Mallinckrodt. In 2005 Aravis, through its Biotech venture I fund, had joined the initial Series A financing of Ikaria Inc, together with 5am, Venrock and Arch. Over time through various innovative M&A and financing steps the company has grown into a highly profitable specialty company. The purchase by Mallinckrodt follows last years’ partial sale to Madison Dearborne and the listing of Ikaria’s spin out Bellorophon (BLPH; NASDAQ).
PDF Download

read more »

March 10, 2015

Ajinomoto project moves into the next phase triggering a milestone payment to Evolva

Evolva (SIX: EVE) today announces that Ajinomoto Co. Inc., Japan, has confirmed that Evolva has completed the first R&D phase in their collaboration and that the collaboration is moving into its next phase. The ultimate objective of the collaboration is the joint development of novel fermentation production routes for a natural functional ingredient for application in Personal Care. Evolva has developed an innovative process that allows Ajinomoto to manufacture the target ingredient. In recognition of the progress and several new findings, Ajinomoto will make a milestone payment to Evolva.
PDF Download - English Version
PDF Download - German Version

read more »

February 27, 2015

Biotie Financial Statement Release 2014

Biotie Financial Statement Release 2014 - This is a summary of the financial statement report 2014 published today.

Company Highlights
October - December 2014 :

- Preparations to advance tozadenant into Phase 3 development in Parkinson's disease as part of Biotie's proprietary portfolio continued during the quarter. The Phase 3 program is expected to start recruiting patients in the middle of 2015.

- Biotie advanced SYN120, a 5-HT6 / 5-HT2a antagonist, into Phase 2 development. The SYNAPSE study, a Phase 2a clinical study in patients with Parkinson's disease dementia, started in December 2014. The study is largely funded by The Michael J. Fox Foundation (MJFF).

- Biotie's partner H. Lundbeck A/S (Lundbeck) continued the rollout of Selincro in Europe and it has now been introduced in 26 European markets. Favorable reimbursement decisions have been issued in a number of European markets, including France, Spain and the United Kingdom, where NICE issued its final positive guidance in November 2014.

- Annual impairment review of intangible assets and goodwill resulted in a non-cash impairment charge of EUR 27.6 million in respect of nepicastat and SYN120.

- Biotie's revenue in Q4 2014 was EUR 1.9 million (EUR 5.8 million) and the financial result was a net loss of EUR 32.4 million (net profit of EUR 1.7 million).

- Biotie ended 2014 with liquid assets of EUR 32.4 million (EUR 35.9 million, 30 September 2014). Operating cash flow for the full year was a net outflow of EUR 14.1 million (net inflow of EUR 10.6 million).

PDF Download

read more »

February 16, 2015

Aravis to present at the Innovationsforum Energie in Zurich on the 20th of March

Aravis has been invited to speak at the 5th Innovationsforum Energie in Zurich on 20th March 2015. Besides sharing practical insights from Aravis experiences in Investment in the energy sector, the following pertinent issues will be addressed:
- Analysing the market to ascertain what is the appetite of investors for European Infrastructure;
- How do Financial Investors view investments in the Energy sector today;
- What are some possible collaborations models between utilities and financial investors when financing energy infrastructure projects?

read more »

February 13, 2015

Bellerophon Therapeutics Announces Pricing of Its Initial Public Offering

Bellerophon Therapeutics announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Bellerophon. In addition, Bellerophon has granted the underwriters an option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount.  Bellerophon's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "BLPH" on February 13, 2015.  The offering is expected to close on February 19, 2015, subject to customary closing conditions.
PDF Download

read more »

February 12, 2015

MerLion announces FDA approval of finafloxacin otic suspension - First novel drug from a Singapore company to achieve FDA approval

MerLion Pharmaceuticals (MerLion), a biopharmaceutical company headquartered in Singapore with clinical development operations in Berlin, Germany, today announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as “swimmer’s ear”, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections.
PDF Download

read more »

February 09, 2015

Evolva provides financial and project update

Evolva (SIX: EVE) today provides a financial and project update.According to the provisional, unaudited financials, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014.
PDF Download - English Version
PDF Download - German Version
 

read more »

January 29, 2015

Aravis sponsors the Wind Risk Management and Mitigation Forum in London on the 4th and 5th of February

Aravis is proud to sponsor the Wind Risk Management and Mitigation Forum taking place in London on the 4th and 5th of February. The conference is organised by Wind Power Monthly, which is widely regarded as the most prestigious magazine in the wind energy sector. In addition, on the second day Aravis will be presenting the topic “Assessing The Impact Of Weather Risk On Cash Flow”. We are excited about the event and are looking forward to meeting you at the conference.

read more »

January 19, 2015

Evolva and Cargill to collaborate on second family of ingredients

Evolva Holding SA (“Evolva”; SIX: EVE) and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.
PDF Download - English Version
PDF Download - German Version

read more »

January 08, 2015

Evolva and L’Oréal reach first milestone in innovative cosmetics ingredient project

Evolva Holding SA (SIX: EVE) today announces the successful completion of the first part of its R&D collaboration with L’Oréal. The parties have agreed to move into the next phase of the multi-year programme.
PDF Download - English Version
PDF Download - German Version

read more »